Lab21 reinforces “UK molecular Dx leadership” with Delphic buy
This article was originally published in Clinica
Lab21 has consolidated its presence in the UK molecular diagnostics market by purchasing bankrupt Delphic Diagnostics from its administrators BDO. Delphic (London, UK) is a laboratory offering pharmacology, virology, therapeutic drug monitoring and specialist clinical trial services to the pharma industry. The laboratory also has specific expertise in HIV and hepatitis, personalised medicine and companion diagnostics. Cambridge, UK-based Lab21 said that the deal would contribute “substantial” sales in 2010 and be accretive to its earnings from early next year. Financial details of the acquisition were not revealed. This deal is part of Lab21’s buy-and-build strategy and is the firm’s third acquisition this year, following deals for Biotec Laboratories in March and Plasmatec Laboratory Products in May (www.clinica.co.uk, May 20 2009).
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals